Loading...
Iloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management
Reyad, Ayman Antoun Mishriky, Raafat
Reyad, Ayman Antoun
Mishriky, Raafat
Authors
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2018-07-02
Submitted date
Alternative
Abstract
Iloperidone is a new atypical antipsychotic drug approved by FDA for the treatment of schizophrenia. In this article, we searched the published randomized controlled trials (RCT) and other literature to review the efficacy and safety of iloperidone using the following database (Science Direct, PubMed) and illustrate its role in the management of schizophrenia. Iloperidone showed efficacy by causing significant improvements in psychiatric scales such as Positive and Negative Syndrome scale (PANSS) and clinical global impressions (CGI). Iloperidone was associated with a number of common side effects such as metabolic and cardiovascular side effects. This review illustrated that iloperidone was well tolerated with significant improvements in disease severity and symptom intensity control in patients suffering with schizophrenia, however, iloperidone was associated with a significantly higher risk of metabolic and cardiovascular side effects with minimal extrapyramidal side effects. These findings would guide psychiatrists and pharmacists in their clinical role for supporting the care of psychiatric patients.
Citation
Reyad, AA., Mishriky, R. (2018) 'Iloperidone - new second generation antipsychotic: Pharmacological aspects and schizophrenia clinical management', International Journal of Current Medical and Pharmaceutical Research,
Publisher
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Type
Journal article
Language
en
Description
Series/Report no.
ISSN
2395-6429